{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:37:22Z","timestamp":1769121442046,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.neuropharm.2012.04.007","type":"journal-article","created":{"date-parts":[[2012,4,21]],"date-time":"2012-04-21T17:41:47Z","timestamp":1335030107000},"page":"202-214","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression"],"prefix":"10.1016","volume":"66","author":[{"given":"Z.A.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Sukoff Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Pulicicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lotarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.N.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kouranova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.H.","family":"Andree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.T.","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.V.","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rosenzweig-Lipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.H.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.04.007_bib1","first-page":"247","article-title":"Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688","volume":"48","author":"Ametamey","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/mp.2008.106","article-title":"Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole","volume":"15","author":"Banasr","year":"2010","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jmg.2008.063701","article-title":"A\u00a0pilot open label, single dose trial of fenobam in adults with fragile X syndrome","volume":"46","author":"Berry-Kravis","year":"2009","journal-title":"Journal of Medical Genetics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0091-3057(02)00828-6","article-title":"Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone","volume":"73","author":"Brodkin","year":"2002","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.npp.1300540","article-title":"The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[lsqb](2-methyl-1,3-thiazol-4-yl)ethynyl[rsqb]pyridine (MTEP) in rodent models of anxiety","volume":"29","author":"Busse","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib8","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0028-3908(88)90189-X","article-title":"Learning impairment in rats by N-methyl-D-aspartate receptor antagonists","volume":"27","author":"Danysz","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2008.129","article-title":"Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease","volume":"34","author":"De Leonibus","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuroscience.2009.03.038","article-title":"Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models","volume":"161","author":"Engin","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report","volume":"165","author":"Fava","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pnpbp.2007.07.027","article-title":"Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus","volume":"32","author":"Garcia","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.biopsych.2009.02.027","article-title":"Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1","volume":"66","author":"Garcia-Garcia","year":"2009","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1526-4637.2002.02029.x","article-title":"Successful treatment of a nine-year case of complex regional pain syndrome type-I (reflex sympathetic dystrophy) with intravenous ketamine-infusion therapy in a warfarin-anticoagulated adult female patient","volume":"3","author":"Harbut","year":"2002","journal-title":"Pain Medicine"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"Hashimoto","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/syn.10261","article-title":"Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in\u00a0vitro and in\u00a0vivo","volume":"50","author":"Heidbreder","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.neuropharm.2008.03.004","article-title":"WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic\/antidepressant agent","volume":"54","author":"Hughes","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1471-4159.2010.06761.x","article-title":"Metabotropic glutamate receptors (mGluRs) regulate noxious stimulus-induced glutamate release in the spinal cord dorsal horn of rats with neuropathic and inflammatory pain","volume":"114","author":"Kumar","year":"2010","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jneumeth.2004.11.008","article-title":"Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat","volume":"144","author":"LaBuda","year":"2005","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S0033291709006035","article-title":"Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) report","volume":"40","author":"Leuchter","year":"2010","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1023648923447","article-title":"Enhancement of antidepressant potency by a potentiator of AMPA receptors","volume":"23","author":"Li","year":"2003","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of [alpha]-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543781003691832","article-title":"Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?","volume":"19","author":"Marin","year":"2010","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2006.04.037","article-title":"Antidepressant-like effects of ceftriaxone in male C57BL\/6J mice","volume":"61","author":"Mineur","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib30","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2006.03.036","article-title":"Correlation between plasma levels of glutamate, alanine and serine with severity of depression","volume":"30","author":"Mitani","year":"2006","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib31","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1124\/jpet.109.154138","article-title":"The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in\u00a0vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine","volume":"330","author":"Montana","year":"2009","journal-title":"Journal of Pharmacology & Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0b013e31802e0002","article-title":"Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment?: a double-blind, placebo-controlled, clinical trial","volume":"27","author":"Mowla","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib33","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.bjp.0703715","article-title":"Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism","volume":"131","author":"O'Leary","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2007.04.007","article-title":"Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs","volume":"115","author":"Palucha","year":"2007","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.pbb.2005.06.015","article-title":"Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist","volume":"81","author":"Palucha","year":"2005","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90516-9","article-title":"Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression","volume":"263","author":"Papp","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004714-198204000-00010","article-title":"Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study","volume":"2","author":"Pecknold","year":"1982","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","article-title":"Riluzole in the treatment of mood and anxiety disorders","volume":"22","author":"Pittenger","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.089839","article-title":"Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity","volume":"315","author":"Porter","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbr.2010.03.039","article-title":"Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction","volume":"212","author":"Roberts","year":"2010","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004714-199902000-00013","article-title":"Effects of SSRIs on sexual function: a critical review","volume":"19","author":"Rosen","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archpsyc.61.7.705","article-title":"Subtype-specific alterations of {gamma}-aminobutyric acid and glutamate in patients with major depression","volume":"61","author":"Sanacora","year":"2004","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0885-3924(99)00125-6","article-title":"NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials","volume":"19","author":"Sang","year":"2000","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1025389031000146773","article-title":"LY354740, an mGlu2\/3 receptor agonist as a novel approach to treat anxiety\/stress","volume":"6","author":"Schoepp","year":"2003","journal-title":"Stress"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib46","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.55.12.1121","article-title":"Treating major depression in primary care practice: an update of the agency for health care policy and research practice guidelines","volume":"55","author":"Schulberg","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejphar.2009.12.039","article-title":"Metabotropic glutamate receptor subtype 5 antagonism in learning and memory","volume":"639","author":"Simonyi","year":"2010","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib48","first-page":"1267","article-title":"Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents","volume":"295","author":"Spooren","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00213-007-0924-7","article-title":"A\u00a0novel approach for predicting antidepressant-induced sexual dysfunction in rats","volume":"195","author":"Sukoff Rizzo","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.110.177378","article-title":"The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise?","volume":"338","author":"Sukoff Rizzo","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib51","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1124\/jpet.106.118604","article-title":"Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in\u00a0vitro and in\u00a0vivo models of chronic pain","volume":"322","author":"Sullivan","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib52","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.bjp.0703923","article-title":"Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist","volume":"132","author":"Tatarczynska","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A\u00a0randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.04.007_bib55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuropharm.2009.09.005","article-title":"Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression","volume":"58","author":"Zink","year":"2010","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812001426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812001426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T17:05:34Z","timestamp":1713891934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812001426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":55,"alternative-id":["S0028390812001426"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.04.007","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}